Go to:
Logótipo
Você está em: Start > Publications > View > Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas
Map of Premises
Principal
Publication

Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas

Title
Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas
Type
Article in International Scientific Journal
Year
2004
Authors
Faleiro Rodrigues, C
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Macedo Pinto, I
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Pereira, D
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Lopes, C
(Author)
ICBAS
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Journal
Title: Annals of OncologyImported from Authenticus Search for Journal Publications
Vol. 15
Pages: 1535-1542
ISSN: 0923-7534
Publisher: Elsevier
Other information
Authenticus ID: P-000-85G
Abstract (EN): Purpose: To analyse the negative versus positive immunoexpression of E-cadherin in patients with primary ovarian carcinomas, and determine its significance in relation to clinicopathological features, overall and recurrence-free survival (RFS). Patients and methods: The protein expression of E-cadherin was immunohistochemically evaluated in formalin-fixed, paraffin-embedded samples in 104 patients with primary ovarian carcinomas. The clinicopathological factors studied were age, FIGO staging, histological type, tumour differentiation, the appearance of the ovarian capsule, peritoneal implants and residual tumour after cytoreductive surgery. Overall survival and RFS were evaluated using the Kaplan-Meier method, and multivariate analysis was completed using the Cox regression model. Results: Of the 104 carcinomas, negative E-cadherin immunoexpression was observed in seven (7%) cases, and positive immunoexpression in 97 (93%). E-cadherin categorised into negative versus positive expression did not associate with any of the established clinicopathological parameters. However, negative E-cadherin expression significantly predicted a poorer overall survival when compared with positive expression (P=0.006). In the multivariate analyses, negative E-cadherin and the presence of residual tumour after cytoreductive surgery were independent prognostic factors for survival (P=0.014 and P=0.034, respectively). Conclusions: The presence of residual tumour after primary cytoreductive surgery and negative E-cadherin expression seem to be useful markers in patients with ovarian carcinomas likely to have an unfavourable clinical outcome. The assessment of E-cadherin immunoreactivity may be a useful prognostic indicator in ovarian cancer, complementary to established prognostic factors.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 8
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

Loss of beta-catenin is associated with poor survival in ovarian carcinomas (2004)
Article in International Scientific Journal
Faleiro Rodrigues, C; Macedo Pinto, I; Pereira, D; Lopes, C
Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas (2004)
Article in International Scientific Journal
Faleiro Rodrigues, C; Macedo Pinto, I; Pereira, D; Ferreira, VM; Lopes, C

Of the same journal

Intratumoral heterogeneity in gastric cancer: a new challenge to face (2017)
Another Publication in an International Scientific Journal
Alsina, M; Gullo, I; Carneiro F
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) (2015)
Another Publication in an International Scientific Journal
Michiels, S; Negreiros, I; Offersen, BV; Llorca, FP; Pruneri, G; Roche, H; Russell, NS; Fernando Schmitt; Servent, V; Thuerlimann, B; Untch, M; van der Hage, JA; van Tienhoven, G; Wildiers, H; Yarnold, J; Bonnetain, F; Mathoulin Pelissier, S; Bellera, C; Dabakuyo Yonli, TS; Gourgou Bourgade, S...(mais 25 authors)
European Consensus Conference for external quality assessment in molecular pathology (2013)
Another Publication in an International Scientific Journal
van Krieken, JH; Siebers, AG; Normanno, N; Blackhall, F; Boone, E; Botti, G; Carneiro F; Celik, I; Ciardiello, F; Magrassi, F; Lanzara, A; Cree, IA; Deans, ZC; Dequeker, E; Edsjo, A; Groenen, PJTA; Kamarainen, O; Kreipe, HH; van Krieken, JH; Ligtenberg, MJL...(mais 16 authors)
Role of imatinib in progesterone-dependent breast cancer cells (2007)
Other Publications
da roche, as; azevedo, i; soares, r
Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation (2013)
Article in International Scientific Journal
Ribeiro, C; Campelos, S; Moura, CS; Machado JC; Justino, A; Parente, B

See all (23)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Medicina Dentária da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z  I Guest Book
Page created on: 2025-07-07 at 01:20:10 | Acceptable Use Policy | Data Protection Policy | Complaint Portal